MNOV
MediciNova, Inc.
Biotechnology
Market Cap$70M
5Y Perf.-75.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MNOV vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.63B
5Y Perf.-37.1%
MNOV vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MNOV | PRAX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $70M | $9.63B |
| Revenue (TTM) | $410K | $-92K |
| Net Income (TTM) | $-12M | $-327M |
| Gross Margin | 7.6% | — |
| Operating Margin | -32.4% | — |
| Total Debt | $194K | $110K |
| Cash & Equiv. | $31M | $357M |
MNOV vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MNOV
PRAX
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| MediciNova, Inc. (MNOV) | 100 | 25.0 | -75.0% |
| Praxis Precision Me… (PRAX) | 100 | 62.9 | -37.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNOV vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNOV leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Praxis Precision Medicines, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MNOV
MediciNova, Inc.
The Income Pick
MNOV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.31
- EPS growth -4.3%
- Lower volatility, beta 0.31, Low D/E 0.5%, current ratio 8.16x
Best for: income & stability and growth exposure
PRAX
Praxis Precision Medicines, Inc.
The Long-Run Compounder
PRAX is the clearest fit if your priority is long-term compounding.
- -20.1% 10Y total return vs MNOV's -80.1%
- 2.4% margin vs MNOV's -29.3%
- +7.7% vs MNOV's -4.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNOV | -8.8% revenue growth vs PRAX's -100.0% |
| Quality / Margins | PRAX | 2.4% margin vs MNOV's -29.3% |
| Stability / Safety | MNOV | Beta 0.31 vs PRAX's 1.55 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PRAX | +7.7% vs MNOV's -4.0% |
| Efficiency (ROA) | MNOV | -26.3% ROA vs PRAX's -40.2%, ROIC -85.5% vs -65.0% |
MNOV vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
MNOV vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRAXLAGGINGMNOV
MNOVMediciNova, Inc.
1leads
PRAXPraxis Precision Medi…
2leads
6 Total Categories
CATEGORYLEADERvs MNOVMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MNOV1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MNOV leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MNOV and PRAX operate at a comparable scale, with $409,657 and -$92,000 in trailing revenue.
| Metric | MNOVMediciNova, Inc. | PRAXPraxis Precision … |
|---|---|---|
| RevenueTrailing 12 months | $409,657 | -$92,000 |
| EBITDAEarnings before interest/tax | -$13M | -$357M |
| Net IncomeAfter-tax profit | -$12M | -$327M |
| Free Cash FlowCash after capex | -$10M | -$283M |
| Gross MarginGross profit ÷ Revenue | +7.6% | — |
| Operating MarginEBIT ÷ Revenue | -32.4% | — |
| Net MarginNet income ÷ Revenue | -29.3% | — |
| FCF MarginFCF ÷ Revenue | -23.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +4.7% | +2.7% |
MNOV leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MNOV and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MNOVMediciNova, Inc. | PRAXPraxis Precision … |
|---|---|---|
| Market CapShares × price | $70M | $9.6B |
| Enterprise ValueMkt cap + debt − cash | $40M | $9.3B |
| Trailing P/EPrice ÷ TTM EPS | -5.96x | -24.72x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 171.21x | — |
| Price / BookPrice ÷ Book value/share | 1.69x | 8.54x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MNOV and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
MNOV delivers a -28.9% return on equity — every $100 of shareholder capital generates $-29 in annual profit, vs $-43 for PRAX. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MNOV's 0.00x.
| Metric | MNOVMediciNova, Inc. | PRAXPraxis Precision … |
|---|---|---|
| ROE (TTM)Return on equity | -28.9% | -43.0% |
| ROA (TTM)Return on assets | -26.3% | -40.2% |
| ROICReturn on invested capital | -85.5% | -65.0% |
| ROCEReturn on capital employed | -28.0% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.00x | 0.00x |
| Net DebtTotal debt minus cash | -$31M | -$357M |
| Cash & Equiv.Liquid assets | $31M | $357M |
| Total DebtShort + long-term debt | $194,331 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
PRAX leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $7,918 today (with dividends reinvested), compared to $3,488 for MNOV. Over the past 12 months, PRAX leads with a +775.0% total return vs MNOV's -4.0%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs MNOV's -13.2% — a key indicator of consistent wealth creation.
| Metric | MNOVMediciNova, Inc. | PRAXPraxis Precision … |
|---|---|---|
| YTD ReturnYear-to-date | +7.5% | +16.4% |
| 1-Year ReturnPast 12 months | -4.0% | +775.0% |
| 3-Year ReturnCumulative with dividends | -34.7% | +1976.5% |
| 5-Year ReturnCumulative with dividends | -65.1% | -20.8% |
| 10-Year ReturnCumulative with dividends | -80.1% | -20.1% |
| CAGR (3Y)Annualised 3-year return | -13.2% | +174.9% |
PRAX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MNOV and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
MNOV is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 93.6% from its 52-week high vs MNOV's 73.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MNOVMediciNova, Inc. | PRAXPraxis Precision … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.29x | 1.40x |
| 52-Week HighHighest price in past year | $1.96 | $356.00 |
| 52-Week LowLowest price in past year | $1.17 | $35.18 |
| % of 52W HighCurrent price vs 52-week peak | +73.0% | +93.6% |
| RSI (14)Momentum oscillator 0–100 | 55.8 | 55.6 |
| Avg Volume (50D)Average daily shares traded | 47K | 378K |
Evenly matched — MNOV and PRAX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MNOVMediciNova, Inc. | PRAXPraxis Precision … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $548.80 |
| # AnalystsCovering analysts | — | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRAX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). MNOV leads in 1 (Income & Cash Flow). 2 tied.
Best OverallPraxis Precision Medicines,… (PRAX)Leads 2 of 6 categories
Loading custom metrics...
MNOV vs PRAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MNOV or PRAX a better buy right now?
Analysts rate Praxis Precision Medicines, Inc.
(PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MNOV or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -20. 8%, compared to -65. 1% for MediciNova, Inc. (MNOV). Over 10 years, the gap is even starker: PRAX returned -20. 9% versus MNOV's -80. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MNOV or PRAX?
By beta (market sensitivity over 5 years), MediciNova, Inc.
(MNOV) is the lower-risk stock at 0. 29β versus Praxis Precision Medicines, Inc. 's 1. 40β — meaning PRAX is approximately 376% more volatile than MNOV relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 0% for MediciNova, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MNOV or PRAX?
On earnings-per-share growth, the picture is similar: MediciNova, Inc.
grew EPS -4. 3% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MNOV or PRAX?
Praxis Precision Medicines, Inc.
(PRAX) is the more profitable company, earning 0. 0% net margin versus -29. 3% for MediciNova, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRAX leads at 0. 0% versus -32. 4% for MNOV. At the gross margin level — before operating expenses — MNOV leads at 7. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MNOV or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MNOV or PRAX better for a retirement portfolio?
For long-horizon retirement investors, MediciNova, Inc.
(MNOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29)). Both have compounded well over 10 years (MNOV: -80. 5%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MNOV and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.